Table 2.
Factors associated with time to discontinuation of oral bisphosphonates (n=1487)
| Univariable | Multivariable | |||||||
|---|---|---|---|---|---|---|---|---|
| Maintained (n=686) | Discontinued (n=801) | HRR | 95% CI | p-value | HRR | 95% CI | p-value | |
| Age group at initiation: | ||||||||
| <70 years | 158 (23.0%) | 188 (23.5%) | REF | |||||
| 70–79 years | 266 (38.8%) | 317 (39.6%) | 0.99 | 0.82 to 1.18 | 0.88 | 1.16 | 0.94 to 1.44 | 0.17 |
| ≥80 years | 262 (38.2%) | 296 (37.0%) | 1.01 | 0.81 to 1.25 | 0.95 | 1.26 | 1.04 to 1.52 | 0.02* |
| Sex (% female) | 527 (76.9 %) | 640 (80.0%) | 1.04 | 0.85 to 1.28 | 0.69 | 1.04 | 0.83 to 1.3 | 0.71 |
| Health cover: | ||||||||
| Private and Other | 98 (14.3%) | 160 (20%) | REF | |||||
| GMS | 562 (81.9%) | 528 (66%) | 0.49 | 0.38 to 0.64 | <0.01* | 0.49 | 0.36 to 0.66 | <0.01* |
| DVC | 26 (3.8%) | 112 (14%) | 1.18 | 0.86 to 1.63 | 0.30 | 1.11 | 0.78 to 1.57 | 0.57 |
| Osteoporosis diagnosis | 211 (30.8%) | 229 (28.6%) | 0.90 | 0.73 to 1.09 | 0.27 | 0.86 | 0.70 to 1.05 | 0.14 |
| Fracture history | 82 (12%) | 67 (8.4%) | 0.82 | 0.64 to 1.04 | 0.11 | 0.82 | 0.64 to 1.05 | 0.11 |
| Calcium/vitamin D prescription | 589 (85.9%) | 634 (79.2%) | 0.74 | 0.62 to 0.89 | <0.01* | 0.79 | 0.66 to 0.93 | <0.01* |
| Number medications in previous 12 months: | ||||||||
| 0 to 5 | 151 (22%) | 252 (31.5%) | REF | |||||
| 6 to 10 | 217 (31.6%) | 250 (31.2%) | 0.71 | 0.60 to 0.85 | <0.01* | 0.82 | 0.69 to 0.98 | 0.03* |
| 11 to 15 | 177 (25.8%) | 158 (19.7%) | 0.64 | 0.49 to 0.83 | <0.01* | 0.77 | 0.59 to 1.01 | 0.06 |
| > 15 | 141 (20.6%) | 141 (17.6%) | 0.70 | 0.57 to 0.85 | <0.01* | 0.83 | 0.66 to 1.05 | 0.12 |
| Dosing frequency: | ||||||||
| Weekly | 624 (91%) | 697 (87%) | REF | |||||
| Monthly | 62 (9%) | 104 (13%) | 1.28 | 1.03 to 1.59 | 0.02* | 1.21 | 0.97 to 1.50 | 0.09 |
GMS general medical services scheme, DVC doctor visit card
*p<0.05